These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32171597)

  • 1. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data.
    Earla JR; Paranjpe R; Kachru N; Hutton GJ; Aparasu RR
    Res Social Adm Pharm; 2020 Dec; 16(12):1670-1676. PubMed ID: 32171597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescribing of disease modifying agents in older adults with multiple sclerosis.
    Talwar A; Earla JR; Hutton GJ; Aparasu RR
    Mult Scler Relat Disord; 2022 Jan; 57():103308. PubMed ID: 35158421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.
    Earla JR; Hutton GJ; Thornton JD; Aparasu RR
    Mult Scler Relat Disord; 2020 Oct; 45():102334. PubMed ID: 32629400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis.
    Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
    Explor Res Clin Soc Pharm; 2021 Jun; 2():100021. PubMed ID: 35481133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.
    Li J; Chikermane SG; Earla JR; Hutton GJ; Aparasu RR
    Mult Scler Relat Disord; 2022 Apr; 60():103703. PubMed ID: 35278846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis.
    Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
    Patient Prefer Adherence; 2020; 14():2187-2199. PubMed ID: 33177813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis.
    Earla JR; Hutton GJ; Thornton DJ; Chen H; Johnson ML; Aparasu RR
    Pharmacotherapy; 2021 May; 41(5):440-450. PubMed ID: 33641232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid Prescribing Among Outpatients with Rheumatoid Arthritis.
    Huang Y; Rege S; Chatterjee S; Aparasu RR
    Pain Med; 2021 Oct; 22(10):2224-2234. PubMed ID: 33565582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-Label Prescribing for Children with Migraines in U.S. Ambulatory Care Settings.
    Lai LL; Koh L; Ho JA; Ting A; Obi A
    J Manag Care Spec Pharm; 2017 Mar; 23(3):382-387. PubMed ID: 28230456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing Patterns for Atopic Dermatitis in the United States.
    Pona A; Cline A; Kolli S; Feldman SF; Fleischer AFJ
    J Drugs Dermatol; 2019 Oct; 18(10):987-990. PubMed ID: 31584776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decline in dopamine agonists prescribing and characteristics of drugs prescribed during ambulatory office visits for restless legs syndrome: the National Ambulatory Medical Care Survey 2007-2015.
    Kim J; Hartzema AG
    Sleep Med; 2019 Feb; 54():238-243. PubMed ID: 30590306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Prescribing Trends for High-Risk Anticholinergic Medications in Older Adults.
    Rhee TG; Choi YC; Ouellet GM; Ross JS
    J Am Geriatr Soc; 2018 Jul; 66(7):1382-1387. PubMed ID: 29582410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing trends for the outpatient treatment of adolescents and young adults with type 2 diabetes mellitus.
    Phan H; Porter K; Sill B; Nahata MC
    J Manag Care Pharm; 2012 Oct; 18(8):607-14. PubMed ID: 23127148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inappropriate medication prescribing for the elderly by office-based physicians.
    Aparasu RR; Fliginger SE
    Ann Pharmacother; 1997; 31(7-8):823-9. PubMed ID: 9220038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia.
    Bhattacharya R; Chatterjee S; Carnahan RM; Aparasu RR
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):434-41. PubMed ID: 22030114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
    Lundy J; Craig BM
    Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic prescribing without documented indication in ambulatory care clinics: national cross sectional study.
    Ray MJ; Tallman GB; Bearden DT; Elman MR; McGregor JC
    BMJ; 2019 Dec; 367():l6461. PubMed ID: 31826860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis disease-modifying therapy prescribing patterns in Ontario.
    Marriott JJ; Mamdani M; Saposnik G; Gomes T; Manno M; O'Connor PW
    Can J Neurol Sci; 2013 Jan; 40(1):67-72. PubMed ID: 23250130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of Opioid Prescribing for Nonmalignant Chronic Pain in US Outpatient Settings.
    Rasu RS; Knell ME
    Pain Med; 2018 Mar; 19(3):524-532. PubMed ID: 28340230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical antipsychotic prescribing in elderly patients with depression.
    Rege S; Sura S; Aparasu RR
    Res Social Adm Pharm; 2018 Jul; 14(7):645-652. PubMed ID: 28826692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.